TONIX PHARMACEUTICALS HOLDING CORP. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum
TONIX PHARMACEUTICALS HOLDING CORP. (TNXP) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum of 4.32% for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum · last filed 2026-08-10
- TONIX PHARMACEUTICALS HOLDING CORP. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2026-03-31 was 4.05%.
- TONIX PHARMACEUTICALS HOLDING CORP. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2024-03-31 was 5.33%, a 32.59% increase year-over-year.
- TONIX PHARMACEUTICALS HOLDING CORP. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2023-03-31 was 4.02%, a 81.08% increase year-over-year.
- TONIX PHARMACEUTICALS HOLDING CORP. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2022-03-31 was 2.22%, a 65.67% increase year-over-year.
- TONIX PHARMACEUTICALS HOLDING CORP. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2025 was 4.30%, a 19.32% decline from fiscal 2024.
- TONIX PHARMACEUTICALS HOLDING CORP. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2024 was 5.33%, a 22.53% increase from fiscal 2023.
- TONIX PHARMACEUTICALS HOLDING CORP. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2023 was 4.35%, a 42.62% increase from fiscal 2022.
- TONIX PHARMACEUTICALS HOLDING CORP. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2022 was 3.05%, a 87.12% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 6 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | 4.32% 10-Q · filed 2026-08-10 | ||||
| 2026-03-31 | 4.05% 10-Q · filed 2026-05-11 | ||||
| 2025-12-31 | 4.30% 10-K · filed 2026-03-12 | ||||
| 2025-09-30 | 4.30% 10-Q · filed 2025-11-10 | ||||
| 2025-06-30 | 4.30% 10-Q · filed 2026-08-10 | ||||
| 2024-12-31 | 5.33% 10-K · filed 2026-03-12 | ||||
| 2024-09-30 | 5.33% 10-Q · filed 2025-11-10 | ||||
| 2024-06-30 | 5.33% 10-Q · filed 2025-08-11 | ||||
| 2024-03-31 | 5.33% 10-Q · filed 2025-05-12 | ||||
| 2023-12-31 | 4.35% 10-K · filed 2025-03-18 | ||||
| 2023-09-30 | 4.35% 10-Q · filed 2024-11-12 | ||||
| 2023-06-30 | 4.02% 10-Q · filed 2024-08-16 | ||||
| 2023-03-31 | 4.02% 10-Q · filed 2024-05-13 | ||||
| 2022-12-31 | 3.05% 10-K · filed 2024-04-01 | ||||
| 2022-09-30 | 3.05% 10-Q · filed 2023-11-09 | ||||
| 2022-06-30 | 3.05% 10-Q · filed 2023-08-10 | ||||
| 2022-03-31 | 2.22% 10-Q · filed 2023-05-08 | ||||
| 2021-12-31 | 1.63% 10-K · filed 2023-03-13 | ||||
| 2021-09-30 | 1.63% 10-Q · filed 2022-11-07 | ||||
| 2021-06-30 | 1.63% 10-Q · filed 2022-08-08 | ||||
| 2021-03-31 | 1.34% 10-Q · filed 2022-05-09 | ||||
| 2020-12-31 | 1.25% 10-K · filed 2022-03-14 | ||||
| 2020-09-30 | 1.25% 10-Q · filed 2021-11-08 | ||||
| 2020-06-30 | 1.25% 10-Q · filed 2021-08-09 | 125.00% 10-Q · filed 2020-08-10 | |||
| 2020-03-31 | 1.25% 10-Q · filed 2021-05-10 | ||||
| 2019-12-31 | 2.54% 10-K · filed 2021-03-15 | ||||
| 2019-09-30 | 2.54% 10-Q · filed 2020-11-09 | ||||
| 2019-06-30 | 254.00% 10-Q · filed 2020-08-10 | 2.54% 10-Q · filed 2019-08-12 | |||
| 2019-03-31 | 2.54% 10-Q · filed 2020-05-12 | ||||
| 2018-12-31 | 2.81% 10-K · filed 2020-03-24 | ||||
| 2018-09-30 | 2.81% 10-Q · filed 2019-11-08 | ||||
| 2018-06-30 | 2.81% 10-Q · filed 2019-08-12 | ||||
| 2018-03-31 | 2.79% 10-Q · filed 2019-05-13 | ||||
| 2017-12-31 | 2.33% 10-K · filed 2019-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |